Focus on nilutamide: A nonsteroidal antiandrogen for treatment of advanced prostate cancer

Formulary

Volumn 31, Issue 2, 1996, Pages 105-112

  Martin, William R ^a,b  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMINOTRANSFERASE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; FLUTAMIDE; GONADORELIN AGONIST; LUTEINIZING HORMONE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANTINEOPLASTIC ACTIVITY; BONE PAIN; CANCER INHIBITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HOT FLUSH; HUMAN; INTERSTITIAL PNEUMONIA; NAUSEA; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PROSTATE CANCER; REVIEW; SURVIVAL RATE; VISUAL DISORDER;

EID: 0030053155     PISSN: 00986909     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Budman DR. Investigational Drugs. In: Perry MC, ed. The Chemotherapy Sourcebook. Baltimore: Williams and Wilkins; 1992:439-96.
2. Moguilewsky M, Fiet J, Touremine C, et al. Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer J Steroid Biochem Mol Biol 1986;24:139-46.
3. Creaven PJ, Pendyala L, Tremblay D. Pharmacokinetics and metabolism of nilutamide. Urology 1991;37(suppl):13-9.
4. Prescribing Information, Bicalutamide (Casodex) 50 mg tablets. Wilmington, DE: Zeneca Pharmaceuticals, 1995.
5. Soloway MS, Matzkin H. Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 1993;71 (suppl 3):1083-8.
6. Pendyala L, Creaven PJ, Huben R, et al. Pharmacokinetics of anandron in patients with advanced carcinoma of the prostate Cancer Chemother Pharmcol 1988;22.69-76.
7. Aisner J, Eisenberger M, Fontana JA. Hormonal agents for the treatment of cancer. In. Perry MC, ed. The Chemotherapy Sourcebook. Baltimore Williams and Wilkins; 1992.413-29.
8. McLeod DG Antiandrogen drugs. Cancer 1993.71:1046-9.
9. Prescribing Information, Flutamide (Eulexin) Capsules. Kenilworth, NJ: Schering Corp: 1989, 1991
10. Decensi AU, Boccardo F, Guarneri D, et al Monotherapy with nilutamide, a pure nonsteroidal antiandrogen in untreated patients with metastatic carcinoma of the prostrate: The Italian prostatic cancer project. J Urol 1991;146 377-81.
11. Faure N, Lemay A, Laroche B, et al Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma Prostate 1983,4 601-24
12. Kuhn JM, Billebaud T, Navratil H, et al Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989;321:413-7
13. Béland G, Elhilali M, Fradet Y, et al. Total androgen blockade versus castration in metastatic cancer of the prostate. Motta M, Serio M, eds. In: Hormonal Therapy of Prostate Cancer: Basic and Therapeutic Aspects Medicom, Amsterdam 1988 302-11
14. Janknegt RA, Abbou CC, Bartoletti R, et al Orchlectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149:77-82
15. Béland G, Elhilali M, Fradet Y, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1990;66:1074-9
16. Bertagna C, DeGéry A, Hucher M, et al. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer A meta-analysis of seven randomized double-blind trials (1056 Patients). Br J Urol 1994,73:396-402.
17. Harnois C, Malenfant M, Dupont A, et al Ocular toxicity of anandron in patients treated for prostatic cancer. Br J Ophthalmol 1986;70:471-3.
18. Béland G, Elhilali M, Fradet Y, et al Total androgen blockade for metastatic cancer of the prostate. Am J Clin Oncol 1988,11(suppl 2):S187-90.
19. The Canadian Anandron Study Group. Total androgen ablation in the treatment of metastatic prostatic cancer. Semin Urol 1990;8:159-65
20. Beland G, Elhilali M, Fradet Y, et al Total androgen ablation: Canadian experience Urol Clin North Am 1991; 18:75-82.
21. Crawford ED, Nahors WL. Total androgen ablation: American experience. Urol Clin North Am 1991;18.55-63